Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients

摘要: Certain host single nucleotide polymorphisms (SNPs) affect the likelihood of a sustained virological response (SVR) to treatment in subjects infected with hepatitis C virus (HCV). SNPs promoters interleukin (IL)-10 (-1082 A/G, rs1800896), myxovirus resistance protein 1 (-123 C/A, rs17000900 and -88 G/T, rs2071430) tumour necrosis factor (TNF) (-308 G/A, rs1800629 -238 rs361525) genes outcome PEGylated α-interferon plus ribavirin therapy were investigated. This analysis was performed 114 Brazilian, HCV genotype 1-infected patients who had SVR 85 non-responders 64 relapsers. A significantly increased risk having null observed carrying at least one allele positions -308 [odds ratios (OR) = 2.58, 95% confidence intervals (CI) 1.44-4.63, p 0.001] or (OR 7.33, CI 3.59-14.93, < 0.001) TNF promoter. The relapsing also elevated (-308: OR 2.87, 1.51-5.44, 0.001; -238: 4.20, 1.93-9.10, 0.001). Multiple logistic regression diplotypes showed that two copies an even higher 16.43, 5.70-47.34, 6.71, 2.18-20.66, No statistically significant association found between other under study anti-HCV response.